FOLFOX Regimen
Information
- Drug Name
- FOLFOX Regimen
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal cancer |
GSTP1 c.[313A>G;341=] ( ENST00000398606.10 ) GSTP1 c.[313A>G;341=] ( ENST00000398606.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Common Germline | 4 | 19922504 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Patients with the GSTP1 I105V variant had greater ... | GSTP1 |
GSTP1 c.[313A>G;341=] ( ENST00000398606.10 ) GSTP1 c.[313A>G;341=] ( ENST00000398606.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03186326 | Active, not recruiting | Phase 2 | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | April 24, 2018 | May 31, 2023 |
| NCT05394740 | Active, not recruiting | Phase 1/Phase 2 | Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | June 6, 2022 | November 2025 |
| NCT05312398 | Active, not recruiting | Phase 2 | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen | July 15, 2021 | June 15, 2026 |
| NCT05108428 | Active, not recruiting | Early Phase 1 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | December 23, 2021 | October 2026 |
| NCT04380337 | Active, not recruiting | Phase 2 | Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer | May 21, 2020 | January 17, 2026 |
| NCT03904043 | Active, not recruiting | N/A | Non-Operative Management and Early Response Assessment in Rectal Cancer | July 1, 2020 | April 30, 2026 |
| NCT03883802 | Active, not recruiting | Phase 2 | Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer | April 12, 2019 | December 14, 2024 |
| NCT00059930 | Active, not recruiting | Phase 1 | Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer | January 2003 | June 2024 |
| NCT00873275 | Active, not recruiting | Phase 1 | Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | March 11, 2009 | January 13, 2025 |
| NCT03861702 | Active, not recruiting | Phase 2 | Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: | September 2, 2020 | August 2024 |
| NCT00958737 | Active, not recruiting | Phase 3 | Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer | May 12, 2009 | December 2023 |
| NCT03635021 | Active, not recruiting | Phase 3 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer | October 15, 2018 | June 28, 2025 |
| NCT03483038 | Active, not recruiting | Phase 2 | A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | December 13, 2018 | December 2024 |
| NCT00016978 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan | April 2001 | |
| NCT00025142 | Completed | Phase 2 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | July 2001 | November 2006 |
| NCT00039611 | Completed | N/A | Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | May 2002 | October 2007 |
| NCT01498289 | Completed | Phase 2 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | February 2012 | September 19, 2019 |
| NCT03254394 | Completed | Phase 1/Phase 2 | Lidocaine for Oxaliplatin-induced Neuropathy | September 15, 2017 | April 1, 2021 |
| NCT00066274 | Completed | Phase 2 | Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | July 23, 2002 | April 1, 2007 |
| NCT00070213 | Completed | Phase 3 | Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | September 2003 | June 1, 2011 |
| NCT00003287 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer | March 1998 | |
| NCT00004102 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | January 1999 | |
| NCT00004127 | Completed | Phase 2 | Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach | February 2000 | August 2003 |
| NCT00103298 | Completed | Phase 2 | Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | December 2004 | July 2006 |
| NCT00006050 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | April 4, 1999 | April 4, 2003 |
| NCT00364013 | Completed | Phase 3 | PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | August 1, 2006 | March 22, 2013 |
| NCT03164382 | Completed | Phase 3 | Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma | March 1, 2017 | November 30, 2020 |
| NCT00873756 | Completed | Phase 1 | A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | May 2009 | April 2014 |
| NCT00008060 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer | May 2000 | December 2003 |
| NCT01418222 | Completed | Phase 2 | FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer | September 14, 2011 | March 18, 2013 |
| NCT00008294 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | August 2000 | |
| NCT00016198 | Completed | Phase 2 | Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer | May 2001 | December 2010 |
| NCT06253611 | Not yet recruiting | Phase 2 | First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer | March 2024 | March 2029 |
| NCT06154538 | Recruiting | Phase 2 | Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer | November 1, 2023 | November 1, 2028 |
| NCT05024097 | Recruiting | Phase 2 | A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. | March 31, 2022 | December 2027 |
| NCT05033522 | Recruiting | Phase 2/Phase 3 | Immunotherapy for Advanced Liver Cancer | August 1, 2023 | December 1, 2025 |
| NCT06123455 | Recruiting | Phase 2 | Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer | August 1, 2023 | July 31, 2025 |
| NCT03801876 | Recruiting | Phase 3 | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | March 15, 2019 | December 21, 2031 |
| NCT06003998 | Recruiting | Phase 2 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab | December 27, 2022 | January 1, 2025 |
| NCT04595266 | Recruiting | Phase 2 | Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease | June 29, 2021 | January 2025 |
| NCT05476796 | Recruiting | Phase 2 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer | June 23, 2023 | January 2027 |
| NCT05712356 | Recruiting | Phase 2 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors | August 24, 2023 | December 2025 |
| NCT05864105 | Recruiting | Phase 2 | PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma | April 22, 2022 | June 30, 2026 |
| NCT03597581 | Recruiting | Phase 1 | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | June 5, 2018 | December 31, 2024 |
| NCT03548961 | Suspended | Phase 2 | Organ Preservation in Early Rectal Cancer Patients | May 11, 2018 | March 1, 2027 |
| NCT00043004 | Terminated | Phase 2 | Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer | May 2002 | |
| NCT00003260 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer | January 1998 | |
| NCT03377842 | Unknown status | Phase 2 | Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer | January 31, 2018 | September 1, 2020 |
| NCT01167725 | Unknown status | Phase 3 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | August 2010 | |
| NCT00884767 | Unknown status | Phase 2 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | September 2007 | |
| NCT00008281 | Unknown status | Phase 3 | Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | October 2000 | |
| NCT00006479 | Unknown status | Phase 3 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | September 2000 | |
| NCT00006468 | Unknown status | Phase 3 | Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | January 2000 | |
| NCT00006115 | Unknown status | Phase 2 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | April 1999 | |
| NCT00004206 | Unknown status | Phase 2 | Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer | September 1999 | |
| NCT02590367 | Unknown status | Phase 2/Phase 3 | Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy | August 2015 | October 2017 |
| NCT03760614 | Withdrawn | Phase 1 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | January 2021 | November 2022 |
| NCT01270438 | Withdrawn | Phase 2 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | December 2010 | August 2013 |
| NCT03982121 | Withdrawn | Phase 1 | Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy | June 4, 2019 | February 12, 2020 |